Ltr Pharma
LTR Pharma is an Australian drug development company focused on men's health, specifically commercializing a rapid-onset, on-demand therapeutic nasal spray for erectile dysfunction. Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, aiming for faster action and improved spontaneity compared to existing ED therapies.
Short position
Ltr Pharma (ASX:LTP) has 0.08% of its shares on issue reported as short positions as of 5 Oct 2026, or about 147,793 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.53% in July 2024. LTP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Ltr Pharma (LTP) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXFirst ROXUS Prescriptions Fulfilled in the United States
other announcement
Google NewsLTR Pharma (ASX:LTP) Gains 5% as SPONTAN Data Builds the Regulatory Picture - Kalkine
LTR Pharma (ASX:LTP) Gains 5% as SPONTAN Data Builds the Regulatory Picture Kalkine
Clinical and Commercial Update - Investor Webinar
other announcement
Notice of Annual General Meeting/Proxy Form
other announcement
Application for quotation of securities - LTP
other announcement
Application for quotation of securities - LTP
other announcement
LTR Expands Men's Health Portfolio with KYZATREX Pilot
other announcement
LTR Pharma (ASX:LTP) Rises As US Commercial Pathway Expands - Kalkine
LTR Pharma (ASX:LTP) Rises As US Commercial Pathway Expands Kalkine
LTR Pharma (ASX:LTP) posts 93% response in 147-patient SPONTAN study as US launch nears - Stocks Down Under
LTR Pharma (ASX:LTP) posts 93% response in 147-patient SPONTAN study as US launch nears Stocks Down Under
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Why LTR Pharma (ASX:LTP) Shares Are in Focus After a Key U.S. Agreement? - Kalkine
Why LTR Pharma (ASX:LTP) Shares Are in Focus After a Key U.S. Agreement? Kalkine
LTR Executes U.S. Commercial Agreement with Strive
other announcement
LTR Executes Definitive U.S. Commercial Agreement with Shed
other announcement
Is LTR Pharma (ASX: LTP) Losing Momentum After a Strong One-Year Gain? - Kalkine
Is LTR Pharma (ASX: LTP) Losing Momentum After a Strong One-Year Gain? Kalkine
LTR Pharma (ASX:LTP) in Focus as Speculative Interest Shifts - Kalkine
LTR Pharma (ASX:LTP) in Focus as Speculative Interest Shifts Kalkine
Linius Technologies (ASX: LTP) Sparks Fresh Tech Buzz as AI Video and Digital Media Themes Build - Kalkine
Linius Technologies (ASX: LTP) Sparks Fresh Tech Buzz as AI Video and Digital Media Themes Build Kalkine
LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
other announcement
LTR Secures First U.S. Commercial Agreement for ROXUS
other announcement
SPONTAN Phase II data show rapid onset, support FDA pathway
other announcement
SPONTAN Phase II Clinical Study Completes Recruitment
other announcement
SPONTAN Shows Positive Outcomes in Younger Men with ED
other announcement
First Patients Dosed in SPONTAN Phase II Clinical Study
other announcement
Patient Recruitment Commences for SPONTAN Phase II Study
other announcement
SPONTAN Phase 1 Study Accepted for WMSM 2026 Podium
other announcement
TGA Provides Regulatory Clearance for SPONTAN Phase II
other announcement
Ethics Approval Received for SPONTAN Phase II Clinical Study
other announcement
Release of Restricted Securities from ASX Mandatory Escrow
other announcement
Change of Director's Interest Notice - M McGuire
director_dealing announcement
Change of Director's Interest Notice - J Chick
director_dealing announcement
Change of Director's Interest Notice - L Rodne
director_dealing announcement